Core Viewpoint - The cannabis sector is experiencing a surge in stock prices following President Trump's endorsement of hemp-derived CBD, which he claims could revolutionize senior healthcare and serve as an alternative to expensive prescription drugs [1][2]. Industry Developments - Major cannabis companies such as Tilray, Canopy Growth, and Aurora have seen their stock prices jump by double digits in response to the president's comments [2]. - The cannabis sector has been volatile, with some stocks losing value this year while others have gained over 30% [5]. Regulatory Changes - President Trump previously legalized hemp-derived products like CBD through the 2018 Farm Bill and hinted at reclassifying cannabis from a Schedule I drug to a Schedule III drug, which would ease criminal penalties and tax burdens on companies [3][4]. - The reclassification would also facilitate more medical research into cannabis, as new HHS standards acknowledge its accepted medical use and some credible scientific support [4]. Market Implications - The potential reclassification of cannabis could welcome big pharmaceutical companies into the market, although the process remains lengthy [5]. - The current administration has the authority to expedite the reclassification process, which could further impact the cannabis market positively [6].